Discontinued — last reported Q4 '24
Augtyro — Total Revenues
Bristol-Myers Squibb Augtyro — Total Revenues increased by 50.0% to $15.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 1400.0%, from $1.00M to $15.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and growing physician adoption of the therapy, while a decrease may signal competitive pressure or slower-than-expected clinical uptake.
Detailed definition
This metric represents the total gross sales generated by the specific oncology therapeutic product Augtyro. It reflects...
Peer comparison
Comparable to revenue metrics for specific high-growth specialty pharmaceutical products or newly launched oncology assets at peer biopharmaceutical companies.
bmy_segment_augtyro_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00M | $6.00M | $7.00M | $10.00M | $15.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | +500.0% | +16.7% | +42.9% | +50.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | >999% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's augtyro — total revenues?
- Bristol-Myers Squibb (BMY) reported augtyro — total revenues of $15.00M in Q4 2024.
- How has Bristol-Myers Squibb's augtyro — total revenues changed year-over-year?
- Bristol-Myers Squibb's augtyro — total revenues increased by 1400.0% year-over-year, from $1.00M to $15.00M.
- What does augtyro — total revenues mean?
- The total revenue generated from sales of the Augtyro drug.